STOCK TITAN
  1. Home
  2. News
  3. BPTH

Bio-Path Holdings Inc - $BPTH STOCK NEWS

Welcome to our dedicated page for Bio-Path Holdings news (Ticker: $BPTH), a resource for investors and traders seeking the latest updates and insights on Bio-Path Holdings stock.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Bio-Path Holdings's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Bio-Path Holdings's position in the market.

News
Bio-Path Holdings Announces Completion of First Dose Cohort in Phase 1 Clinical Trial Evaluating BP1002 to Treat Refractory/Relapsed Lymphoma and Refractory/Relapsed Chronic Lymphocytic Leukemia Patients
Rhea-AI Summary
Bio-Path Holdings, Inc. (BPTH) completes first dose cohort of Phase 1 clinical trial for BP1002, a potential treatment targeting Bcl-2 protein for refractory/relapsed lymphoma and CLL patients. Preclinical studies show promising results, with the potential for combination therapy with approved agents.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
5.64%
Tags
clinical trial
-
News
Bio-Path Holdings Successfully Completes First Dose Cohort of Phase 1/1b Clinical Trial of BP1002 in Refractory/Relapsed Acute Myeloid Leukemia
Rhea-AI Summary
Bio-Path Holdings, Inc. (NASDAQ: BPTH) has completed the first dose cohort of the Phase 1/1b clinical trial of BP1002, a treatment for refractory/relapsed acute myeloid leukemia (AML) patients, including venetoclax-resistant patients. The study aims to evaluate the safety and efficacy of BP1002 in treating these patients, with plans to assess its combination with decitabine in the Phase 1b portion. The trial is led by renowned medical experts, and the company is optimistic about the potential of BP1002 in providing a promising treatment for patients with limited therapeutic options.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
clinical trial
-
News
Bio-Path Holdings Reports Third Quarter 2023 Financial Results
Rhea-AI Summary
Bio-Path Holdings, Inc. (NASDAQ:BPTH) announced its financial results for the third quarter ended September 30, 2023, highlighting the positive interim data from the Phase 2 study of prexigebersen in combination with decitabine and venetoclax for the treatment of acute myeloid leukemia. The company also reported a net loss of $3.2 million for the quarter, with decreased research and development expenses and general and administrative expenses. The recent corporate developments include a Key Opinion Leader event and a positive analysis of Phase 2 clinical trial results.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.92%
Tags
earnings
News
Bio-Path Holdings to Announce Third Quarter 2023 Financial Results on November 15, 2023
Rhea-AI Summary
Bio-Path Holdings, Inc. (NASDAQ: BPTH) to report Q3 financial results and business overview in live conference call and webcast
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-8.33%
Tags
earnings
-
News
Bio-Path Holdings to Host Virtual Key Opinion Leader Event to Discuss Prexigebersen and Advances in the Treatment Landscape for Acute Myeloid Leukemia
Rhea-AI Summary
Bio-Path Holdings, Inc. will host a virtual key opinion leader event to discuss advances in the treatment landscape for acute myeloid leukemia (AML) and highlight the prexigebersen program. The event will feature presentations and discussions with experts in the field.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
9.52%
Tags
conferences
-
News
Bio-Path Holdings to Present at H.C. Wainwright 25th Annual Global Investment Conference
Rhea-AI Summary
Bio-Path Holdings CEO to present at H.C. Wainwright conference
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
conferences
News
Stonegate Capital Partners Updates Coverage on Bio-Path Holdings, Inc. (BPTH) Q2 23
Rhea-AI Summary
Stonegate Capital Partners Updates Coverage on Bio-Path Holdings, Inc. (NASDAQ: BPTH) for Q2 2023.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
7.89%
Tags
none
-
News
Bio-Path Holdings Reports Second Quarter 2023 Financial Results
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-11.63%
Tags
earnings
-
News
Bio-Path Holdings to Announce Second Quarter 2023 Financial Results on August 15, 2023
Rhea-AI Summary
Bio-Path Holdings to report Q2 financial results on August 15, 2023
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
25.64%
Tags
earnings
News
Bio-Path Holdings, Inc. Announces Pricing of $2.1 Million Public Offering
Rhea-AI Summary
Bio-Path Holdings, Inc. (Nasdaq:BPTH) announced the pricing of a public offering of 3,500,000 shares of common stock with accompanying purchase warrants, generating approximately $2.1 million in gross proceeds. Each share is priced at $0.60 and comes with a purchase warrant to buy one share at the same price, exercisable immediately and expiring in five years.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-46.05%
Tags
offering
Stock BPTH logo
Bio-Path Holdings Inc

Nasdaq:BPTH

BPTH Rankings

N/A Ranked by Market Cap
N/A Ranked by Stock Gains
N/A Ranked by Dividends

BPTH Stock Data

4.26M
628.47k
0.23%
3.73%
9.93%
Medicinal and Botanical Manufacturing
Manufacturing
Link
United States of America
BELLAIRE

About BPTH

bio-path is a publicly traded biotechnology company focused on developing therapeutic products utilizing its proprietary dnabilize™ technology designed to distribute nucleic acid drugs throughout the human body with a simple intravenous infusion. the company’s initial focus is in oncology. bio-path’s lead product candidate, prexigebersen, (bp1001), is in phase ii clinical trials for aml in combination with ldac in elderly de novo patients. the safety segment of the phase ii trial for prexigebersen + dasatinib in blast-phase and accelerated phase cml patients is expected to begin in 2017. bio-path’s second drug candidate, bp1002, is ready for the clinic where it will be evaluated in lymphoma and solid tumors. the technology behind prexigebersen is called dnabilize™ technology. dnabilize is a liposomal antisense dna platform with two critical improvements in oligonucleotide therapeutics. the main benefits to the patient are, 1: we have never had a single patient experience thrombocytopen